Innovative, minimally invasive Medical Prostatic Retraction Device for the treat...
Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
apyx
The first non-surgical repair for Pelvic Organ Prolapse
5M€
Cerrado
UroAct
Restoring a normal life and dignity for women and men suffer...
13M€
Cerrado
Duración del proyecto: 21 meses
Fecha Inicio: 2023-11-20
Fecha Fin: 2025-08-31
Líder del proyecto
BUTTERFLY MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctor’s office, under local anaesthesia.
Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue.
FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.